Two case reports of resensitization to previous chemotherapy with the novel hypoxia-activated hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer patients

Case Reports in Oncology

Volumn 7, Issue 1, 2014, Pages 79-85

  Reid, T ^a   Dad, S ^a   Korn, R ^b   Oronsky, B ^c   Knox, S ^d   Scicinski, J ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Imaging Endpoints Core Lab   (United States)

^c RadioRx Inc   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Epigenetic resensitization; Hypoxia activation; Oxidation

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; DNA METHYLTRANSFERASE 1; DSA RRX 001; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; RRX 001; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CASE REPORT; CHEMOSENSITIZATION; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DEMETHYLATION; DRUG EXPOSURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; ENZYME REPRESSION; EPIGENETICS; HISTOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECTUM HEMORRHAGE; TREATMENT DURATION; TUMOR SUPPRESSOR GENE;

EID: 84900521969     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000358382     Document Type: Article

References (7)

1. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res 2012;72:2600-2608.
2. Bednarski M, Oehler L, Knox S, et al: Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof. US Patent No 7507842B2. 2009.
3. Scicinski J, Oronsky B, Taylor M, et al: Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab Dispos 2012;40:1810-1816.
4. Fens M, Larkin S, Morris C, Fitch W, Scicinski J, Oronsky B, Kuypers F: NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells. Blood (ASH Annual Meeting Abstracts) 2011;118:Abstract 2125.
5. Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors. Cancer Res 2012;72(suppl 1):4371.
6. Haggar FA, Boushey RP: Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009;22:191-197.
7. Hess GP, Wang PF, Quach D, Barber B, Zhao Z: Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 2010;6:301-307.